New treatment options in hairy cell leukemia with focus on BRAF inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2594
Abstract: Hairy cell leukemia (HCL) responds initially very well to chemotherapy with purine analogues. However, up to 50% of patients relapse, often multiple times, and become progressively less sensitive to these myelotoxic and immune‐suppressive drugs. At… read more here.
Keywords: treatment; cell leukemia; hairy cell; braf ... See more keywords
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04795-x
Abstract: Both characteristics and optimal treatment strategy for hairy cell leukemia-variant (HCL-v) remain elusive due to its rarity. We retrospectively analyzed the clinical features of HCL-v and the efficacy of first-line treatment options in a large… read more here.
Keywords: leukemia variant; purine nucleoside; treatment; cell leukemia ... See more keywords
Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04800-3
Abstract: Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. However, there is limited real-world data on… read more here.
Keywords: cladribine; hairy cell; treated cladribine; cell leukemia ... See more keywords
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology Reports"
DOI: 10.1007/s11912-022-01285-1
Abstract: This article aims to bring an update on the recent discoveries in hairy cell leukemia (HCL), especially findings in pathophysiology and therapeutic advances. Major discoveries have been made in genetics and epigenetics of HCL. Moreover,… read more here.
Keywords: therapeutic advances; cell leukemia; hairy cell; hcl ... See more keywords
[Hairy cell leukemia].
Sign Up to like & getrecommendations! Published in 2019 at "Presse medicale"
DOI: 10.1016/j.lpm.2019.07.026
Abstract: Hairy cell leukemia (HCL) is a well-defined entity. Proliferation with hair cells, morphological aspects of hairy cells are easy to identify. Hairy cells express markers CD11c, CD25, CD103 and CD123. In 80% of cases, a… read more here.
Keywords: cell; cell leukemia; hairy; hairy cell ... See more keywords
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0210-1
Abstract: This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL… read more here.
Keywords: cell; response; moxetumomab pasudotox; cell leukemia ... See more keywords
Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2023.2193323
Abstract: ABSTRACT Introduction Hairy cell leukemia (HCL) is a rare subtype of indolent lymphoid leukemia originating from a mature B lymphocyte. The standard first-line treatment for classic HCL, and HCL variant (HCLv), consists of purine nucleoside… read more here.
Keywords: hairy cell; leukemia; cell leukemia; hcl ... See more keywords
Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL‐V)
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17055
Abstract: Department of Haematology, Aneurin Bevan University Health Board, Abergavenny, Department of Cellular Pathology and All Wales Lymphoma Panel, University Hospital of Wales, Cardiff, Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres,… read more here.
Keywords: haematology; hairy; department; hcl ... See more keywords
Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues
Sign Up to like & getrecommendations! Published in 2017 at "Histopathology"
DOI: 10.1111/his.13206
Abstract: Hairy cell leukaemia (HCL) is a rare B cell neoplasm that mainly affects bone marrow (BM), peripheral blood (PB) and spleen. Involvement of lymph nodes and extranodal structures is considered infrequent. Herein we describe our… read more here.
Keywords: cell; cell leukaemia; lymph nodes; hairy cell ... See more keywords
Abstract 19: Braf(v600e) mutation together with loss of trp53 or pten drives the origination of hairy cell leukemia from b-lymphocyte
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-19
Abstract: Hairy cell leukemia (HCL) is a B-lymphoma induced by BRAF(V600E) mutation. However, introducing BRAF(V600E) in B-lymphocytes fails to induce hematological malignancy, suggesting that BRAF(V600E) needs concurrent mutations for driving HCL ontogeny. To resolve this issue,… read more here.
Keywords: v600e; braf v600e; hairy cell;
Durable Responses with Vemurafenib plus Rituximab in Hairy-Cell Leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-071
Abstract: Of 30 patients with relapsed or refractory hairy-cell leukemia, 87% experienced complete responses. read more here.
Keywords: responses vemurafenib; durable responses; cell leukemia; hairy cell ... See more keywords